Unicycive Therapeutics, Inc.
UNCY- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001766140
No open-market purchases or sales by Unicycive Therapeutics, Inc. insiders were filed in the last 90 days; 79 institutions reported holding it in 13F filings for Q2 2026, worth $54.6M in total; no superinvestor holds it.
Q3 2025 vs. Q2 2025
How the institutions holding Unicycive Therapeutics, Inc. changed between Q2 2025 and Q3 2025.
All holders in Q3 2025All holders in Q2 2025
| Measure | Q2 2025 | Q3 2025 | Change |
|---|---|---|---|
| Holders | 20 | 30 | +10 |
| Shares | 5.14M | 6.29M | +1.14M (+22.2%) |
| Value | $24.6M | $27.4M | +$2.80M (+11.4%) |
New holders (13)
Institutions that held Unicycive Therapeutics, Inc. at the end of Q3 2025 but not at the end of Q2 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Squarepoint Ops LLC | 117,327 | $511.5K | 0.00% |
| Goldman Sachs Group Inc | 45,200 | $197.1K | 0.00% |
| Citadel Advisors LLC | 41,674 | $181.7K | 0.00% |
| XTX Topco Ltd | 37,823 | $164.9K | 0.01% |
| BlackRock, Inc. | 36,355 | $158.5K | 0.00% |
| Chicago Partners Investment Group LLC | 26,961 | $127.3K | 0.00% |
| Cubist Systematic Strategies, LLC | 23,947 | $104.4K | 0.00% |
| Citigroup Inc | 6,692 | $29.2K | 0.00% |
| UBS Group AG | 5,445 | $23.7K | 0.00% |
| Rockefeller Capital Management L.P. | 500 | $2.18K | 0.00% |
| TFC Financial Management | 300 | $1.31K | 0.00% |
| Fortitude Family Office, LLC | 107 | $467 | 0.00% |
| BNP Paribas Arbitrage, SA | 55 | $240 | 0.00% |
Sold out (3)
Institutions that held Unicycive Therapeutics, Inc. at the end of Q2 2025 and filed for Q3 2025 without it.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| JPMorgan Chase & Co | 21,709 | $103.6K |
| Renaissance Technologies LLC | 11,790 | $56.2K |
| Lazard Asset Management LLC | 11,575 | $55.0K |